EUCTR2013-004105-11-DE进行中（未招募）不适用
A Phase 2, Open-label, Randomized Study to Evaluate Safety and Efficacy of Momelotinib in Subjects with Polycythemia Vera or Essential Thrombocythemia
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years old
- •2.Diagnosis of either PV or ET as defined by the 2008 WHO Diagnostic Criteria
- •3.Requires treatment for PV or ET, in the opinion of the study investigator
- •4.Intolerant of, resistant to, or refuses current or available treatment for PV or ET
- •5.Direct bilirubin = 2.0 x upper limit of normal (ULN)
- •6.AST (SGOT) and ALT (SGPT) = 3X ULN
- •7.Calculated creatinine clearance (CrCl) of = 45 mL/min
- •8.Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2
- •9.Life expectancy > 24 weeks
- •10.Negative serum pregnancy test for female subjects (unless surgically sterile or greater than two years postmenopausal)
- •11.Male subjects and female subjects of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
- •12.Females who are nursing must agree to discontinue nursing before the first dose of IP
- •13.Able to comprehend and willing to sign informed consent form (ICF)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 20
排除标准
- •1.Prior splenectomy
- •2.Uncontrolled intercurrent illness including, but not limited to, active uncontrolled infection (subjects receiving outpatient antibacterial and/or antiviral treatments for infection that is under control or as infection prophylaxis may be included in the study), active or chronic bleeding event within 4 weeks prior to first dose of IP, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled cardiac arrhythmia, or psychiatric illness/social situation that would limit compliance with study requirements as judged by treating physician
- •3.History of a concurrent or second malignancy except for adequately treated local basal cell or squamous cell carcinoma of the skin, cervical carcinoma in situ, superficial bladder cancer, asymptomatic prostate cancer without known metastatic disease and with no requirement for therapy or requiring only hormonal therapy and with normal prostate-specific antigen for = 1 year prior to randomization, adequately treated Stage 1 or 2 cancer currently in complete remission (CR), or any other cancer that has been in CR for = 5 years.
- •4.Major surgery within 28 days of first dose of IP
- •5.Known positive status for human immunodeficiency virus (HIV)
- •6.Chronic active or acute viral hepatitis A, B, or C infection (testing required for hepatitis B and C), or hepatitis B or C carrier
- •7.Myeloproliferative neoplasm-directed therapy, other than aspirin, hydroxyurea, anagrelide, and/or phlebotomy, within 21 days prior to the first dose of IP
- •8.Anagrelide within 7 days prior to the first dose of IP
- •9.Unresolved non-hematologic toxicities from prior therapies that are > CTCAE Grade 1
- •10.Presence of peripheral neuropathy = Grade 2
- •11.Incomplete recovery from any surgery performed within 4 weeks prior to the first dose of IP
- •12.Unwilling or unable to take oral medication
- •13.Prior use of a JAK1 or JAK2 inhibitor
- •14.Use of strong CYP3A4 inducers within 1 week prior to the first dose of IP
- •15.Known hypersensitivity to the study investigational medicinal products, the metabolites, or formulation excipients
- •16. QTc interval > 450msec, unless attributed to bundle branch block
研究者
相似试验
进行中（未招募）
1 期
A Phase 2, Open-label, Randomized Study to Evaluate Prophylactic Interventions on Talquetamab-related Oral Toxicitymultiple myelomaCTIS2023-506260-14-00Janssen - Cilag International152
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerEUCTR2016-001402-41-HUGilead Sciences, Inc144
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaMedDRA version: 20.0Level: HLTClassification code 10017812Term: Gastric neoplasms malignantSystem Organ Class: 100000004856EUCTR2016-001402-41-ITGILEAD SCIENCES INCORPORATED144
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerunresectable or recurrent gastric or gastroesophageal junction adenocarcinomaEUCTR2016-001402-41-BEGilead Sciences, Inc144
进行中（未招募）
1 期
A Clinical Study to evaluate the efficacy and safety of GS-5745 in combination with Nivolumab compared to Nivolumab alone in patients with stomach cancerEUCTR2016-001402-41-DEGilead Sciences, Inc120